NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SeLux Diagnostics

SeLux Diagnostics

Private
MassachusettsHealthcare & Life Scienceshttps://seluxdx.com/

Last Round

Series C

Extension

Apr 1, 2024

Total Funding Raised

$268.25M

Company Overview

SeLux Diagnostics is a biotechnology company that develops a rapid phenotyping platform for antibiotic susceptibility testing and the diagnosis of infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

antimicrobial susceptibility testingASTrapid diagnosticssepsis diagnosticsclinical microbiologymedical devicediagnostic platformblood culture testingrazor-and-blade modelbacterial infection testingpoint of care diagnosticslab automationphenotypic testingdiagnostic consumablesantibiotic stewardship

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SeLux Diagnostics Comparables

Compare SeLux Diagnostics with similar companies based on industry and business-model similarity.

SeLux Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PhAST Diagnostics
89%
First Light Diagnostics, Inc.
88%
Pattern Bioscience
88%

SeLux Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionApr 1, 2024
Series C ExtensionFeb 13, 2024
GrantJul 12, 2022
DebtJun 1, 2022
Series CFeb 28, 2022
Grant
Oct 19, 2021

Key People

Founding team and executive leadership

Steve Lufkin

Chief Executive Officer

Executive Team

Jack Percoskie

Chief Financial Officer

Executive Team

Michele Healy

Chief Financial Officer

Executive Team

SeLux Diagnostics Investors

Notable investors and investment history

SeLux Diagnostics investors
InvestorRounds
RA Capital ManagementSeries B, Series C, Series C Extension
NIH RADxGrant
Northpond VenturesSeries C, Series B, Series C Extension
Public Health Emergency Medical Countermeasures EnterpriseGrant
Schooner CapitalSeries C, Series B, Series C Extension
Biomedical Advanced Research and Development AuthorityGrant
Oxford FinanceDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2024

    $48M round led by RA Capital Management.

  • Feb 13, 2024

    $48M round led by RA Capital Management.

SeLux Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SeLux Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SeLux Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMassachusetts
Employee Range14
Year Founded2014
Last FundingApr 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.